Development and validation of dissolution procedures

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 3, 2011, Pages 50-56

  Vaghela, Bhavesh J ^a   Kayastha, Rajan ^a   Bhatt, Nayana ^a   Pathak, Nimish ^a   Rathod, Dashrath ^a  

^a C U Shah College of Pharmacy and Research   (India)

Author keywords

Dissolution apparatus; Dissolution medium; Dissolution procedure development; Quality control; Validation parameters

Indexed keywords

EID: 84867743069     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Abdou Hamed M. Dissolution, Bioavailability and Bioequivalence. First edition. Mack Publishing House (2001) 56-89.
2. Banker GS and Rhodes C. Modern Pharmaceutics. 3rd edition revised and expanded. Marcel dekkar INC. New York. 2002: 67-78.
3. Brahmankar DM. Biopharmaceutics & Pharmacokinetics. First edition. vallabh prakashan (2006) 20-29.
4. Cardot J., Beyssac E, Alric M. Dissolution Technology. Issue 1. February 2000; 9: 341-356.
5. FDA Division of Pharmaceutical Analysis, Mechanical Qualification of Dissolution apparatus 1 and 2. Document # DPA-LOP.002. June 2006; 2. See: http://www.fda.gov/cder/offices/otr/dissolution.pdf.
6. Feidmon. Validation of bio-analytical methods. AAPS PharmSciTech 2004; 5(1): 57-68 Article 22 (www.pharmscitech.org).
7. Frank T. Peters, Hans H. Maurer. bioanalytical method validation. pharmaceutical methods. AAPS PharmSciTech 2004; 5(1): 106-118. Article 22 (www.pharmscitech.org).
8. Gibaldi M and Feidmon S. Model independent Methods used for dissolution data comparison. J.Pharm.Sci. 10. 1997; 56: 1238-1242
9. Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. FDA. August 1997. See: www.fda.gov/cder/guidance/1713bp1.pdf.
10. Guidance for Industry: SUPAC-MR. Modified Release Solid Oral Dosage Forms FDA. September 1997. See: www.fda.gov/cder/guidance/1214fnl.pdf.
11. Guidance for Industry. Waiver of In-Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. FDA. August 2000. See: www.fda.gov/cder/guidance/3618fnl.pdf.
12. Higuchi T. Comparison of dissolution profile. J.Pharm.Sci, 10. 1961; 50:874-875.
13. International Conference on Harmonization, Harmonized Tripartite Guideline. Validation of Analytical Procedures. Text and Methodology. Q2 (R1). November 2005. See www.ICH.org.
14. International Conference on Harmonization (ICH). Validation of Analytical Methods: Definitions and Terminology. ICH Q2A. 1994.
15. International Organization for Standardization. Accuracy (Trueness and Precision) of Measurement Methods and Results. ISO/DIS 5725-1 to 5725-3. 1994.
16. Michael Swartz. Developing and validating dissolution procedures for improved product quality. Pharma Times. 2011; 43: 4-12.
17. Polli, Rekhi, Ausburger Shah. Various media used for dissolution test. J.Pharm.Sci. 1997; 86: 690-700.
18. Robes BR., and Seltzer DJ. Diss. Tech. 2. Issue 2. Spring 1995 : 1-9.
19. S. L. R. Ellison and T. Fearn. Trends in Analalytical Chemistry. 2005; 24: 468.
20. Shargel Leon. Equipments for dissolution test. Generic Drug Product Development. 6th edition. Lippincott Williams And Wilkins. 2007: 83-96.
21. Swartz ME. Analytical Instrument Qualification,.Pharmaceutical Regulatory Guidance Book. Advanstar (publisher). July 2006: 12-16.
22. USP 30-NF 25. December 2007 Chapter 1058.
23. USP 32-NF 27. August 2009. Chapter 621.
24. USP 32-NF 27. August 2009. Chapter 701.
25. USP 32-NF 27. August 2009. Chapter 711.
26. USP 32-NF 27. August 2009. Chapter 724.
27. USP 32-NF 27, August 2009, Chapter 1092.
28. USP 32-NF 27, August 2009, Chapter 1225.